Table 2. Known agents with radioprotective activity.

Radioprotectant type		Agent	Reference	Radioprotectant type		Agent	Reference
Type A				Type C
	A1	Hydroxytryptamine	[24]		C1	Tenovil (rhIL-10)	[107]
		Amifostine	[25]			Dekavil (IL-10/F8 fusion)	[108]
		Cobalt chloride	[30]			SeV- mediated transfer of IL-10 gene	[110]
		Deferoxamine	[31]			IL-10 inducers (Y-40128, WY14643. reboxetine, edelfosine)	[111-114]
		Clioquinol	[34]			Infliximab (anti-TNFα)	[115]
		Isofluran	[35]			Tolcizumab (anti-IL6 Ab)	[116,117]
		Okadaic acid	[36]			IL-6 blockers (A-285222, Baicalein)	[118,119]
		Vanadate	[37]			Anakinra (IL-1 receptor antagonist)	[120]
		Tilorone	[38]			Anti-CD54 Ab	[122]
		Baicalein	[39]			Pravastatin	[124-126]
		FG-4497	[40]		C2	VEGF blockers	[130]
	A2	Superoxide dismutases	[41]			TNP-470	[131]
		Glutathione	[42]			HIF blockers (PX-478, YC-1)	[132,133]
		N-acetyl-cystein	[43]			TGFβ blockers (naringenin, halogunginon, relaxin, SB-525334, SB203580, pirferidone, pentoxyfylline)	[140-148]
		Amifostine (WR-1065)	[25]			PDGFR inhibitors (imatinib, SU9518)	[150,151]
		Fullerenols	[51]			Infliximab (anti-TNFα Ab)	[158]
		Cerium oxide	[52]			HGF gene transfer	[170-172]
		Tempol	[54]			Retinoic acid	[173]
	A3	Amifostine (WR-33278)	[57,58]			Anti-bFGF	[177]
		Resveratrol	[65]			ACE inhibitors	[178]
		Butin	[70]			COX inhibitors	[179]
		Vectors with repair enzymes	[71-75]
Type B				Type D		Amifostine	[191-194]
	B1	Sodium orthovanadate	[79]			INGN201 (p53 gene therapy)	[199]
		Antisense-PUMA	[80]			Mdm2 inhibitors (until-1, MI-219)	[200,201]
		Inhibitors of GSK-3β	[81]			Oblimersen sodium (anti-bcl-2)	[202]
		HPV16 E5 viral protein	[82]			Vanillin derivatives	[209]
		Angiotensin receptor blockers	[83]			Avotermin (TGFβ)	[213]
		Flagellin analogues	[87]			NF-κB inducers	[217]
		RTA401	[88]			Macrophage activation suppressors	[218]
		Autophagy modulators	[90]
	B2	Haemopoietin growth factors	[91,92]	Type E
		Keratinocyte growth factor	[94]			Amifostine and Type A agents
		Becaplermin (rhPDGF-BB)	[95]			Type D agents
		Telbermin (rhVEGF)	[97,98]			Gap junction inhibitors (lindane, TPA)	[226-228]
		FGF-P peptide	[99]			NOS-inhibitors (L-NAME)	[229]
		FGF1:FGF2 chimeric GF	[100]			Macrophage activation inhibitors	[231,232]
		Velafermin (rhFGF-20)	[101]			Demethylation targeting agents	[233]

ACE, angiotensin-converting-enzyme; COX, cyclooxygenase; FGF, fibroblast growth factor; GSK-3β, glycogen synthase kinase 3-beta; HGF, hepatocyte growth factor; HIF, hypoxia inducible factor; HPV, human papillomavirus; IL, interleukin; NOS, nitric oxide synthase; PDGFR, platelet derived growth factor receptor; PUMA, p53 upregulated modulator of apoptosis; TGF, transforming growth factor; TNF, tumour necrosis factor; TNP, methionine aminopeptidase-2 (MetAP-2) inhibitor; VEGF, vascular endothelial growth factor.